Semaglutide, a weight loss medication from Novo Nordisk, is now available in UK pharmacies (as of September 2023); it’s sold under the brand name Wegovy. You’ll also be able to buy Wegovy from approved online retailers.
Research has shown that semaglutide – alongside a lifestyle intervention – can lead to a significant weight loss of between 15-20% after 68 weeks.
In comparison, lifestyle interventions without semaglutide typically lead to a weight loss of around 5-10%.
You can also purchase Wegovy from Second Nature alongside our award-winning weight-loss programme.
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist. GLP-1s are a type of medication that’s used to help with weight loss. They work by mimicking a hormone called GLP-1 that the body naturally produces after eating.
GLP-1 helps to regulate blood sugar levels by stimulating insulin production and slowing down the rate at which food leaves the stomach.
GLP-1 receptor agonists mimic GLP-1 and can be injected under the skin once or twice a day or once a week, depending on the specific medication.
They may cause side effects, such as nausea, vomiting, or constipation, but these usually subside after a few weeks when your body adjusts.
Not a magic pill
Research on GLP-1s has shown that weight regain is very common once the medication has been stopped if the person hasn’t implemented sustainable lifestyle changes.
One trial showed that individuals taking semaglutide lost an average of 17.3% of their body weight after 68 weeks. However, one year after the medication had stopped, they regained 11.6% of their lost weight.
Essentially, your body becomes reliant on the medication to manage your appetite.
If you haven’t made the right changes to your lifestyle before you come off the medication, your appetite and old eating habits will return, and you’ll likely regain much of the lost weight.
Second Nature launches a new Wegovy-supported weight-loss programme
We’re excited to announce that we’ve launched a new Wegovy-supported weight-loss programme.
This will be in combination with our award-winning weight-loss programme, which has over five years of clinical data proving its effectiveness.
Whilst the evidence supporting the use of semaglutide for weight loss is robust, a sustainable lifestyle change is crucial in maintaining that weight loss in the long term.
Wegovy information
| Product name | Wegovy |
| Active ingredient | Semaglutide |
| Manufacturer | Novo Nordisk |
| Price | £229 |
| What’s included? |
|
| Second Nature Trustpilot rating | 4.8/5 |
| Second Nature Trustpilot reviews | 6,888 (as of January 2024) |
| Availability | In stock |
| Description | Once weekly weight-loss injection |
| Administration | Subcutaneous injection (multiple sites like the arm, stomach, or leg) |
| Presentation | Injection pen |
| Available dosage | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg |
| Drug class | GLP-1 receptor agonist |
| When pregnant/breastfeeding | Not permitted |
Why choose Second Nature?
If you’ve made the decision to try a semaglutide prescription (assuming you’re eligible), why should you choose Second Nature’s medication-assisted programme over others?
For peace of mind.
Second Nature is the only UK company that provides private weight-loss injections and is also trusted by the NHS to provide weight-loss services.
The NHS has used Second Nature for over 6 years, and we ensure we abide by the highest levels of data security and patient safety.
With that, we believe there comes a level of authenticity and peace of mind that other providers cannot match (e.g. Boots, Superdrug, Juniper, Numan, Manual, etc.).
Whilst our Wegovy weight-loss programme is a private programme and isn’t yet used by the NHS, we’ve applied the same high standards of data security and patient safety. The programme is science-backed and has been developed by dietitians, nutritionists, and psychologists.
If you want to go with a company with a proven track record of providing the most effective digital weight-loss programme to the NHS (as proven in our official scientific publications in the British Medical Journal, and others), then give us a go.
